Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ranok Starts Trials of BRD4 Protein Degradation Therapy for Solid Tumors

publication date: Aug 24, 2022

Ranok Therapeutics, a Boston-Hangzhou company started US clinical trials of a novel therapy for solid tumor cancers or diffuse large B-cell lymphoma. Ranok develops drug candidates based on its novel approach to protein degradation. The Phase I/II trial will test safety and tolerability of RNK05047, the first therapy based on Ranok's proprietary CHAMP™ technology and the first BRD4 protein degrader to start clinical trials. One year ago, Ranok raised $40 million in a B round from China investors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here